Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists.
Evotec provides bespoke anti-infective drug discovery and development services from target identification to investigational new drug (“IND”) and has an established and proven track record of contributing to the discovery and development of multiple anti-infective agents from pre-clinical candidates through to marketed drugs.
Evotec has established a leading-edge platform enabling the discovery and development of new therapies and vaccines to treat and prevent serious and life-threatening infections arising from Gram-positive and Gram-negative bacteria including multi-drug resistant (“MDR”) organisms, fungal pathogens, viruses and parasites. Evotec’s expertise also reaches beyond conventional antimicrobial agents into multiple alternative platforms such as targeting virulence attributes, specific pathogen antibodies, ‘resistance breakers’, combination therapies, and phage technologies.
Its anti-infective discovery team of >160 FTEs has a breadth of experience with multiple compound classes: small molecules, natural products, biologics, peptides, antibodies, combinations, biocides and vaccines. We carefully evaluate and adopt the most efficient and optimal drug discovery approaches from phenotypic screening to target-based discovery. Evotec has extensive experience in multiple target classes including folate, non-mevalonate, aromatic biosynthesis, protein synthesis, ribosome, virulence attributes and resistance pathways as well as determining the mechanism of action (“MOA”) of new antimicrobials discovered from phenotypic screening.